Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ARTV Stock Alerts

Artiva Biotherapeutics (ARTV) Financials

Artiva Biotherapeutics logo
$9.88 +0.73 (+7.92%)
As of 03:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Artiva Biotherapeutics

Annual Income Statements for Artiva Biotherapeutics

This table shows Artiva Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -29 -65 -84
Consolidated Net Income / (Loss)		 -29 -65 -84
Net Income / (Loss) Continuing Operations		 -29 -66 -84
Total Pre-Tax Income 		-29 -66 -84
Total Operating Income		 -31 -67 -90
Total Gross Profit		 33 0.25 0.00
Total Revenue		 33 0.25 0.00
Operating Revenue		 33 0.25 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 64 68 90
Selling, General & Admin Expense		 14 17 20
Research & Development Expense		 50 50 70
Total Other Income / (Expense), net		 2.02 1.75 5.96
Interest & Investment Income		 2.54 5.35 5.96
Other Income / (Expense), net		 -0.51 -3.60 0.00
Basic Earnings per Share		 ($35.78) ($5.81) ($3.43)
Weighted Average Basic Shares Outstanding		 802.75K 11.26M 24.44M
Diluted Earnings per Share		 ($35.78) ($5.81) ($3.43)
Weighted Average Diluted Shares Outstanding		 802.75K 11.26M 24.44M
Weighted Average Basic & Diluted Shares Outstanding		 - 24.36M 24.72M

Quarterly Income Statements for Artiva Biotherapeutics

This table shows Artiva Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 11 -14 -18 -17 -16 -20 -21 -22 -21 -24
Consolidated Net Income / (Loss)		 11 -14 -18 -17 -16 -20 -21 -22 -21 -24
Net Income / (Loss) Continuing Operations		 11 -14 -18 -17 -16 -20 -21 -22 -21 -24
Total Pre-Tax Income 		11 -14 -18 -17 -16 -20 -21 -22 -21 -24
Total Operating Income		 11 -14 -16 -18 -18 -22 -23 -23 -22 -24
Total Gross Profit		 27 0.25 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 27 0.25 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 27 0.25 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 16 15 16 18 18 22 23 23 22 24
Selling, General & Admin Expense		 2.78 3.59 3.86 4.81 4.95 5.12 4.95 5.26 4.94 5.12
Research & Development Expense		 13 11 12 14 13 17 18 18 17 19
Total Other Income / (Expense), net		 0.47 0.53 -1.68 0.87 2.03 1.86 1.56 1.37 1.16 0.91
Interest & Investment Income		 0.42 0.65 0.68 1.85 2.18 1.86 1.56 1.37 1.16 0.91
Other Income / (Expense), net		 0.05 -0.12 -2.35 -0.98 -0.15 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 $13.98 ($17.24) ($22.00) ($0.92) $34.35 ($0.83) ($0.87) ($0.88) ($0.85) ($0.95)
Weighted Average Basic Shares Outstanding		 806.71K 809.76K 811.21K 18.90M 11.26M 24.34M 24.38M 24.48M 24.44M 24.68M
Diluted Earnings per Share		 $1.62 ($17.24) ($22.00) ($0.92) $34.35 ($0.83) ($0.87) ($0.88) ($0.85) ($0.95)
Weighted Average Diluted Shares Outstanding		 6.97M 809.76K 811.21K 18.90M 11.26M 24.34M 24.38M 24.48M 24.44M 24.68M
Weighted Average Basic & Diluted Shares Outstanding		 - - 24.29M 24.29M 24.36M 24.36M 24.43M 24.54M 24.72M 24.72M

Annual Cash Flow Statements for Artiva Biotherapeutics

This table details how cash moves in and out of Artiva Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -49 -13 -13
Net Cash From Operating Activities		 -47 -55 -77
Net Cash From Continuing Operating Activities		 -48 -55 -77
Net Income / (Loss) Continuing Operations		 -29 -65 -84
Consolidated Net Income / (Loss)		 -29 -65 -84
Depreciation Expense		 2.27 2.43 2.60
Amortization Expense		 -0.46 -2.34 -1.88
Non-Cash Adjustments To Reconcile Net Income		 7.05 6.98 6.82
Changes in Operating Assets and Liabilities, net		 -28 3.23 -0.40
Net Cash From Investing Activities		 -26 -120 63
Net Cash From Continuing Investing Activities		 -26 -120 63
Purchase of Property, Plant & Equipment		 -3.26 -0.64 -2.59
Purchase of Investments		 -50 -176 -45
Sale and/or Maturity of Investments		 27 56 111
Net Cash From Financing Activities		 24 162 0.01
Net Cash From Continuing Financing Activities		 24 162 0.01
Repurchase of Common Equity		 -0.01 -4.18 0.00
Issuance of Common Equity		 0.00 167 0.00
Other Financing Activities, net		 24 -0.10 0.01

Quarterly Cash Flow Statements for Artiva Biotherapeutics

This table details how cash moves in and out of Artiva Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 -12 -5.30 -14 22 -16 -9.63 -1.93 -2.96 1.19 -5.75
Net Cash From Operating Activities		 -11 -11 -15 -14 -12 -15 -20 -23 -19 -15 -21
Net Cash From Continuing Operating Activities		 -11 -11 -15 -14 -12 -15 -20 -23 -19 -15 -21
Net Income / (Loss) Continuing Operations		 11 -12 -14 -18 -17 -16 -20 -21 -22 -21 -24
Consolidated Net Income / (Loss)		 11 -12 -14 -18 -17 -16 -20 -21 -22 -21 -24
Depreciation Expense		 0.56 0.59 0.59 0.60 0.63 0.61 0.63 0.64 0.66 0.67 0.67
Amortization Expense		 -0.16 -0.28 -0.37 -0.27 -0.66 -1.04 -0.72 -0.51 -0.36 -0.29 -0.20
Non-Cash Adjustments To Reconcile Net Income		 1.49 1.28 1.41 4.10 2.88 -1.41 2.04 1.56 1.63 1.59 1.59
Changes in Operating Assets and Liabilities, net		 -24 -0.41 -2.79 -0.36 3.10 3.29 -1.47 -3.44 0.44 4.07 0.51
Net Cash From Investing Activities		 -0.49 -2.67 9.78 1.35 -131 -0.97 9.97 21 16 16 15
Net Cash From Continuing Investing Activities		 -0.43 -2.67 9.78 1.35 -131 -0.97 9.97 21 16 16 15
Purchase of Property, Plant & Equipment		 -0.11 -0.64 -0.02 -0.46 -0.10 -0.06 -0.51 -1.06 -0.60 -0.42 -0.24
Purchase of Investments		 -12 -15 -6.20 -12 -143 -15 -19 -6.07 -13 -7.54 -6.44
Sale and/or Maturity of Investments		 12 13 16 14 12 14 29 28 30 24 22
Net Cash From Financing Activities		 23 0.96 0.00 -1.62 164 -0.03 0.24 -0.07 -0.04 -0.12 -0.11
Net Cash From Continuing Financing Activities		 23 0.96 0.00 -1.62 164 -0.03 0.24 -0.03 -0.17 -0.03 -0.11
Repurchase of Common Equity		 - - - - -2.60 -0.02 0.00 - - - 0.00
Issuance of Common Equity		 - - - - - - 0.00 - - - 0.00
Other Financing Activities, net		 23 0.96 0.00 -0.06 -0.03 -0.01 0.24 -0.03 -0.17 -0.03 -0.11

Annual Balance Sheets for Artiva Biotherapeutics

This table presents Artiva Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 105 210 131
Total Current Assets		 80 189 113
Cash & Equivalents		 54 40 27
Short-Term Investments		 23 145 81
Accounts Receivable		 1.76 0.15 0.07
Prepaid Expenses		 1.09 3.06 4.59
Plant, Property, & Equipment, net		 8.10 6.37 6.62
Total Noncurrent Assets		 17 15 12
Noncurrent Note & Lease Receivables		 0.00 0.26 0.21
Other Noncurrent Operating Assets		 17 14 11
Total Liabilities & Shareholders' Equity		 105 210 131
Total Liabilities		 51 23 21
Total Current Liabilities		 12 12 13
Accounts Payable		 0.61 1.12 0.36
Accrued Expenses		 8.02 7.39 9.60
Other Current Liabilities		 3.60 3.74 3.13
Total Noncurrent Liabilities		 38 11 7.88
Capital Lease Obligations		 0.00 0.04 0.00
Other Noncurrent Operating Liabilities		 38 11 7.88
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -162 187 110
Total Preferred & Common Equity		 -162 187 110
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -162 187 110
Common Stock		 19 433 440
Retained Earnings		 -181 -247 -331
Accumulated Other Comprehensive Income / (Loss)		 0.31 -0.13 0.10

Quarterly Balance Sheets for Artiva Biotherapeutics

This table presents Artiva Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 76 226 191 169 149 106
Total Current Assets		 50 151 170 149 130 89
Cash & Equivalents		 34 56 30 28 26 21
Short-Term Investments		 12 91 136 114 97 66
Accounts Receivable		 1.46 0.70 0.23 0.03 0.08 0.00
Prepaid Expenses		 1.73 3.23 3.81 6.67 6.48 1.96
Plant, Property, & Equipment, net		 7.32 6.86 7.06 6.89 6.98 6.22
Total Noncurrent Assets		 19 68 14 13 12 11
Noncurrent Note & Lease Receivables		 0.29 0.28 0.25 0.23 0.22 0.20
Other Noncurrent Operating Assets		 19 15 14 13 12 11
Total Liabilities & Shareholders' Equity		 76 226 191 169 149 106
Total Liabilities		 51 25 22 20 20 18
Total Current Liabilities		 11 13 12 11 11 11
Accounts Payable		 0.82 1.22 2.04 1.22 0.85 2.29
Accrued Expenses		 6.21 8.34 6.38 5.84 7.03 5.56
Other Current Liabilities		 3.79 3.73 3.79 3.72 3.25 3.04
Total Noncurrent Liabilities		 40 11 10 9.58 8.52 7.23
Capital Lease Obligations		 0.11 0.08 0.01 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 40 11 10 9.58 8.52 7.23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -191 201 169 149 129 88
Total Preferred & Common Equity		 -191 201 169 149 129 88
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -191 201 169 149 129 88
Common Stock		 22 431 436 437 439 442
Retained Earnings		 -213 -231 -267 -288 -310 -354
Accumulated Other Comprehensive Income / (Loss)		 0.12 0.34 0.00 0.00 0.09 -0.02

Annual Metrics And Ratios for Artiva Biotherapeutics

This table displays calculated financial ratios and metrics derived from Artiva Biotherapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 24,289,328.00 24,544,904.00
DEI Adjusted Shares Outstanding		 0.00 24,289,328.00 24,544,904.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.69 -3.42
Growth Metrics		 - - -
Revenue Growth		 0.00% -99.25% -100.00%
EBITDA Growth		 0.00% -141.00% -25.86%
EBIT Growth		 0.00% -127.30% -26.71%
NOPAT Growth		 0.00% -119.37% -33.48%
Net Income Growth		 0.00% -127.62% -28.29%
EPS Growth		 0.00% 83.76% 40.96%
Operating Cash Flow Growth		 0.00% -16.03% -39.47%
Free Cash Flow Firm Growth		 0.00% 0.00% 10.37%
Invested Capital Growth		 0.00% 105.57% 56.09%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -3.15%
EBIT Q/Q Growth		 0.00% 0.00% -4.08%
NOPAT Q/Q Growth		 0.00% 0.00% -4.26%
Net Income Q/Q Growth		 0.00% 0.00% -5.91%
EPS Q/Q Growth		 0.00% 0.00% -110.80%
Operating Cash Flow Q/Q Growth		 0.00% -7.79% -0.10%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% -68.64%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 0.00%
EBITDA Margin		 -87.70% -28,203.19% 0.00%
Operating Margin		 -91.58% -26,805.58% 0.00%
EBIT Margin		 -93.11% -28,238.65% 0.00%
Profit (Net Income) Margin		 -85.75% -26,045.02% 0.00%
Tax Burden Percent		 100.25% 99.76% 100.02%
Interest Burden Percent		 91.87% 92.45% 93.36%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.80% -54.24% -56.55%
Cash Return on Invested Capital (CROIC)		 0.00% -5,642.59% -3,949.80%
Operating Return on Assets (OROA)		 -29.67% -45.05% 0.00%
Return on Assets (ROA)		 -27.32% -41.55% 0.00%
Return on Common Equity (ROCE)		 157.24% -5.54% -56.55%
Return on Equity Simple (ROE_SIMPLE)		 17.73% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -47 -63
NOPAT Margin		 -64.10% -18,763.90% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.42% -13.93% -14.31%
Return On Investment Capital (ROIC_SIMPLE)		 13.25% -25.23% -57.17%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 41.54% 6,854.58% 0.00%
R&D to Revenue		 150.04% 20,051.00% 0.00%
Operating Expenses to Revenue		 191.58% 26,905.58% 0.00%
Earnings before Interest and Taxes (EBIT)		 -31 -71 -90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -71 -89
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 1.31 0.96
Price to Tangible Book Value (P/TBV)		 0.00 1.31 0.96
Price to Revenue (P/Rev)		 4.99 975.44 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 47.30 0.00
Enterprise Value to Revenue (EV/Rev)		 9.15 236.86 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.42 -1.09 -0.99
Leverage Ratio		 1.93 1.31 1.15
Compound Leverage Factor		 1.78 1.21 1.07
Debt to Total Capital		 0.00% 0.02% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.02% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 397.83% 0.00% 0.00%
Common Equity to Total Capital		 -297.83% 99.98% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.62 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.94 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 -0.33 4.65 -1.87
Noncontrolling Interest Sharing Ratio		 397.83% 89.78% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 6.53 15.39 8.61
Quick Ratio		 6.44 15.15 8.26
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -71 -64
Operating Cash Flow to CapEx		 -1,455.80% -8,571.96% -2,966.80%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.32 0.00 0.00
Accounts Receivable Turnover		 19.05 0.26 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 4.14 0.03 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 19.16 1,384.38 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 19.16 1,384.38 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -23 1.26 1.96
Invested Capital Turnover		 -1.48 -0.02 0.00
Increase / (Decrease) in Invested Capital		 0.00 24 0.71
Enterprise Value (EV)		 306 59 -2.71
Market Capitalization		 167 245 105
Book Value per Share		 ($201.83) $7.68 $4.48
Tangible Book Value per Share		 ($201.83) $7.68 $4.48
Total Capital		 54 187 110
Total Debt		 0.00 0.04 0.00
Total Long-Term Debt		 0.00 0.04 0.00
Net Debt		 -77 -185 -108
Capital Expenditures (CapEx)		 3.26 0.64 2.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.38 -9.05 -8.43
Debt-free Net Working Capital (DFNWC)		 68 176 100
Net Working Capital (NWC)		 68 176 100
Net Nonoperating Expense (NNE)		 7.25 18 21
Net Nonoperating Obligations (NNO)		 -77 -185 -108
Total Depreciation and Amortization (D&A)		 1.81 0.09 0.72
Debt-free, Cash-free Net Working Capital to Revenue		 -28.00% -3,605.58% 0.00%
Debt-free Net Working Capital to Revenue		 201.82% 70,270.12% 0.00%
Net Working Capital to Revenue		 201.82% 70,270.12% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.81) ($3.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 11.26M 24.44M
Adjusted Diluted Earnings per Share		 $0.00 ($5.81) ($3.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 11.26M 24.44M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 24.36M 24.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -47 -63
Normalized NOPAT Margin		 -64.10% -18,763.90% 0.00%
Pre Tax Income Margin		 -85.54% -26,107.57% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.04% -6.40% 0.00%

Quarterly Metrics And Ratios for Artiva Biotherapeutics

This table displays calculated financial ratios and metrics derived from Artiva Biotherapeutics' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 24,287,144.00 24,289,328.00 24,363,119.00 24,363,119.00 24,425,762.00 24,544,904.00 24,716,672.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 24,287,144.00 24,289,328.00 24,363,119.00 24,363,119.00 24,425,762.00 24,544,904.00 24,716,672.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -0.72 -0.66 -0.83 -0.87 -0.88 -0.85 -0.95
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% -54.43% -271.82% 0.00% -54.69% -24.52% -16.79% -14.42% -7.62%
EBIT Growth		 0.00% 0.00% -57.23% -277.81% 0.00% -51.72% -23.02% -18.56% -19.12% -10.19%
NOPAT Growth		 0.00% 0.00% -36.92% -218.72% 0.00% -52.99% -40.89% -24.88% -20.08% -10.19%
Net Income Growth		 0.00% 0.00% -58.13% -254.91% 0.00% -45.46% -19.12% -23.21% -29.06% -15.78%
EPS Growth		 0.00% 0.00% -56.14% -156.79% 0.00% 95.19% 96.05% 4.35% -102.47% -14.46%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% -8.03% -37.24% -31.52% -67.94% -65.37% -0.52% -5.59%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -546.66% -45.44% 0.00% 16.43%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 131.59% 324.42% 56.09% -62.38%
Revenue Q/Q Growth		 662.25% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 195.46% 0.00% -26.52% -6.22% 2.61% -18.18% -1.85% 0.38% 4.58% -11.16%
EBIT Q/Q Growth		 192.10% 0.00% -26.89% -4.15% 4.66% -20.42% -2.88% -0.38% 4.21% -11.39%
NOPAT Q/Q Growth		 230.62% 0.00% -11.72% -13.25% 0.38% -21.39% -2.88% -0.38% 4.21% -11.39%
Net Income Q/Q Growth		 199.96% 0.00% -27.79% 2.08% 7.88% -26.19% -4.64% -1.29% 3.51% -13.21%
EPS Q/Q Growth		 111.50% 0.00% -27.61% 95.82% 3,833.70% -102.42% -4.82% -1.15% 3.41% -11.76%
Operating Cash Flow Q/Q Growth		 0.00% -41.32% 9.29% 15.16% -26.17% -35.43% -15.84% 16.46% 23.31% -42.27%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -245.99% 100.00% 0.00% -138.56% 52.46% 22.84% 4.50%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 106.97% -14.72% 125.22% 135.82% -6.29% -68.64% -45.72%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 42.23% -5,734.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 40.56% -5,773.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 40.75% -5,821.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 42.31% -5,562.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 99.87% 100.03% 99.14% 100.02% 100.02% 100.01% 100.01% 99.99%
Interest Burden Percent		 103.85% 95.55% 96.35% 90.44% 88.18% 91.59% 93.16% 94.01% 94.70% 96.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% 0.00% -42.49% -86.18% -47.96% -56.55% -67.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -5,642.59% 0.00% 0.00% 0.00% -3,949.80% -3,217.78%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% 0.00% -42.49% 20.79% -47.96% -56.55% -67.86%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 11 -10 -11 -13 -13 -16 -16 -16 -15 -17
NOPAT Margin		 40.56% -4,041.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% -28.03% -4.65% -1.79% -5.77% -5.60% -3.41% -3.69% -5.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - 5.93% -6.38% -6.85% -9.19% -10.71% -12.40% -13.96% -19.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 10.43% 1,429.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 49.01% 4,444.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 59.44% 5,873.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 11 -15 -19 -19 -18 -22 -23 -23 -22 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11 -14 -18 -19 -19 -22 -23 -23 -22 -24
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.87 1.31 0.43 0.25 0.54 0.96 1.81
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1.87 1.31 0.43 0.25 0.54 0.96 1.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 975.44 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 119.21 47.30 0.00 0.00 0.00 0.00 67.98
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 236.86 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 -1.83 -0.99 -0.99 -0.98 -1.08 -0.98 -0.99 -0.98
Leverage Ratio		 0.00 0.00 3.00 1.12 1.31 1.13 1.41 1.13 1.15 1.16
Compound Leverage Factor		 0.00 0.00 2.89 1.02 1.15 1.04 1.31 1.07 1.09 1.11
Debt to Total Capital		 0.00% 0.00% 0.42% 0.04% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.42% 0.04% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 851.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% -751.70% 99.96% 99.98% 99.99% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 2.62 2.11 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 3.94 3.16 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 5.48 0.60 -0.76 -0.32 -0.16 0.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 124.12% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 4.59 11.33 15.39 13.93 13.84 11.65 8.61 8.16
Quick Ratio		 0.00 0.00 4.43 11.08 15.15 13.62 13.22 11.07 8.26 7.98
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 9.80 -14 0.00 -18 -44 -21 -16 -15
Operating Cash Flow to CapEx		 -9,511.50% -83,811.11% -2,949.35% -12,094.79% -22,890.63% -3,882.78% -2,178.48% -3,200.17% -3,497.86% -8,657.02%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.26 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 1,384.38 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 1,384.38 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 -21 1.47 1.26 2.83 6.68 6.26 1.96 1.07
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.20 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 -21 1.47 0.00 2.83 28 4.78 0.71 -1.77
Enterprise Value (EV)		 0.00 0.00 337 176 59 -93 -106 -53 -2.71 72
Market Capitalization		 167 167 167 375 245 73 37 70 105 159
Book Value per Share		 $0.00 $0.00 ($235.57) $8.28 $7.68 $6.93 $6.12 $5.29 $4.48 $3.55
Tangible Book Value per Share		 $0.00 $0.00 ($235.57) $8.28 $7.68 $6.93 $6.12 $5.29 $4.48 $3.55
Total Capital		 0.00 0.00 25 201 187 169 149 129 110 88
Total Debt		 0.00 0.00 0.11 0.08 0.04 0.01 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.11 0.08 0.04 0.01 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 -46 -200 -185 -166 -142 -123 -108 -87
Capital Expenditures (CapEx)		 0.11 0.02 0.46 0.10 0.06 0.51 1.06 0.60 0.42 0.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 -7.63 -9.36 -9.05 -8.16 -4.07 -4.56 -8.43 -8.92
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 39 137 176 158 138 118 100 78
Net Working Capital (NWC)		 0.00 0.00 39 137 176 158 138 118 100 78
Net Nonoperating Expense (NNE)		 -0.47 3.82 6.51 4.64 3.31 4.79 5.29 5.50 5.42 6.42
Net Nonoperating Obligations (NNO)		 0.00 0.00 -46 -200 -185 -166 -142 -123 -108 -87
Total Depreciation and Amortization (D&A)		 0.40 0.22 0.33 -0.03 -0.43 -0.10 0.13 0.31 0.38 0.47
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -3,605.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 70,270.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 70,270.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($22.00) ($0.92) $34.35 ($0.83) ($0.87) ($0.88) ($0.85) ($0.95)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 811.21K 18.90M 11.26M 24.34M 24.38M 24.48M 24.44M 24.68M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($22.00) ($0.92) $34.35 ($0.83) ($0.87) ($0.88) ($0.85) ($0.95)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 811.21K 18.90M 11.26M 24.34M 24.38M 24.48M 24.44M 24.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.29M 24.29M 24.36M 24.36M 24.43M 24.54M 24.72M 24.72M
Normalized Net Operating Profit after Tax (NOPAT)		 7.57 -10 -11 -13 -13 -16 -16 -16 -15 -17
Normalized NOPAT Margin		 28.39% -4,041.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 42.31% -5,562.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -6.40% 0.00% -3.49% -0.03% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Artiva Biotherapeutics (NASDAQ: ARTV) remains a pre-revenue biotech story, and the latest quarter shows a company still spending heavily on research while relying on its balance sheet and investment portfolio to fund operations. Revenue was still $0 in Q1 2026, while the company posted a net loss of $23.5 million.

From a retail investor perspective, the key question is not profitability yet, but whether Artiva has enough liquidity and whether spending is trending in the right direction. On that front, the company still has a sizable cash/investment base, but operating losses remain persistent.

  • Strong liquidity cushion remains. As of Q1 2026, Artiva reported $20.9 million in cash and $65.8 million in short-term investments, or about $86.7 million combined.
  • Balance sheet is still asset-rich. Total assets were $106.0 million versus total liabilities of $18.1 million, leaving shareholders’ equity at $87.8 million.
  • Operating cash burn improved versus prior periods. Q1 2026 operating cash outflow was $21.0 million, slightly better than the roughly $22.9 million outflow in Q2 2025 and worse than Q4 2025’s $14.7 million, but still far below the levels seen during some earlier periods.
  • Interest income helped offset losses. Q1 2026 interest and investment income was $912,000, which partially softened the operating loss.
  • Shares outstanding remain relatively stable quarter to quarter. Weighted average basic shares were 24.7 million in Q1 2026, only modestly above the prior quarter.
  • No operating revenue yet. Artiva remains pre-commercial, so future value still depends on clinical progress rather than current sales.
  • Most cash generation came from investment maturities. The company generated $22.0 million from sales/maturities of investments in Q1 2026, which is helpful for liquidity but not a recurring operating source.
  • R&D spending stayed elevated. Research and development expense was $19.3 million in Q1 2026, reflecting continued investment in the pipeline.
  • SG&A was also meaningful. Selling, general and administrative expense totaled $5.1 million, so overhead remains a real cash demand.
  • Losses remain substantial. Artiva lost $23.5 million in Q1 2026, compared with a $20.8 million loss in Q4 2025 and $21.3 million in Q2 2025.
  • Operating cash flow is still deeply negative. The company burned $21.0 million in operations in the quarter, which is a major drag on runway.
  • Equity has fallen sharply over the past year. Total common equity dropped from $169.0 million in Q1 2025 to $87.8 million in Q1 2026.
  • Retained losses continue to accumulate. Retained earnings were a large negative $(354.1) million at quarter-end, highlighting the company’s long history of losses.
  • Cash balance declined sequentially. Cash and equivalents fell from $25.5 million in Q3 2025 to $21.0 million in Q1 2026.

Bottom line: Artiva Biotherapeutics has enough liquidity for now, supported by a substantial investment portfolio, but the business is still in a heavy cash-burn phase with no revenue. Investors should watch clinical updates and the pace of operating losses closely, because those will likely drive whether the company can extend its runway without raising additional capital.

07/21/26 01:19 PM ETAI Generated. May Contain Errors.

Artiva Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Artiva Biotherapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Artiva Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$83.87 million in 2025, rising from -$28.72 million in 2023. The previous period was -$65.37 million in 2024. Check out Artiva Biotherapeutics' forecast to explore projected trends and price targets.

Artiva Biotherapeutics' total operating income in 2025 was -$89.81 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $89.81 million

Over the last 2 years, Artiva Biotherapeutics' total revenue changed from $33.49 million in 2023 to $0.00 in 2025, a change of -100.0%.

Artiva Biotherapeutics' total liabilities were at $20.97 million at the end of 2025, a 8.6% decrease from 2024, and a 58.7% decrease since 2023.

In the past 2 years, Artiva Biotherapeutics' cash and equivalents has ranged from $26.70 million in 2025 to $53.50 million in 2023, and is currently $26.70 million as of their latest financial filing in 2025.

Over the last 2 years, Artiva Biotherapeutics' book value per share changed from -201.83 in 2023 to 4.48 in 2025, a change of -102.2%.


Related Companies

Financial statements for NASDAQ:ARTV last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel